UNI-ASIA Logo WATA Logo
Luo Jiamin
Appointment
Luo Jiamin
Associate Chief PhysicianMaster of Oncology, Chongqing Medical UniversityDeputy Director of Oncology Ward II, Chengdu Huanya Hospital
Over 10 years of clinical experience in oncology treatment
Over 10,000 cumulative procedures
Specialties:
Specializes in the application of immunotherapy combined with local therapy for advanced tumors, as well as chemotherapy, targeted therapy and immunotherapy for solid tumors such as lung cancer, liver cancer and colorectal cancer.
Academic Positions
Member, Tumor Interventional and Minimally Invasive Therapy Committee, Chengdu Hi-Tech Medical Association
Member, Oncology Prevention, Screening, Diagnosis, Treatment and Rehabilitation Committee, Chongqing Health Managers Association

Exploring New Paths in Cancer Treatment Through Comprehensive Therapy, and Safeguarding the Light of Life with Compassion

- A Conversation with Dr. Luo Jiamin, Deputy Director of Oncology Ward II, Chengdu Huanya Hospital

Deeply Engaged in Comprehensive Oncology Treatment, Developing Individualized Precision Plans for Cancer Patients Through Immunotherapy-Based Combination Strategies

In the field of comprehensive oncology treatment, there is a physician dedicated to organically integrating cutting-edge immunotherapy concepts with interventional treatment techniques, exploring better individualized treatment strategies for patients with advanced tumors. She previously worked in the Department of Oncology at the Army Medical Center of PLA (formerly Daping Hospital, Army Medical University), where she accumulated solid clinical experience on the platform of a national key clinical oncology specialty. She is Luo Jiamin, currently Deputy Director of Oncology Ward II at Chengdu Huanya Hospital.

Dr. Luo Jiamin graduated from Chongqing Medical University with a master’s degree in oncology. Over more than ten years of clinical practice, she has focused on chemotherapy, targeted therapy and immunotherapy for solid tumors such as lung cancer, liver cancer and colorectal cancer. She consistently integrates standardized diagnosis and treatment concepts with individualized precision plans throughout every aspect of her clinical work, striving to provide high-quality, full-course management services for cancer patients.

In terms of oncology treatment philosophy, Dr. Luo Jiamin specializes in the application of immunotherapy combined with local therapy for advanced tumors. In clinical practice, she has thoroughly summarized the synergistic effects of immune checkpoint inhibitors combined with radiotherapy, interventional therapy and ablation therapy in refractory tumors such as lung cancer with liver metastasis and liver cancer. She is committed to effectively controlling tumors while maximizing preservation of organ function and quality of life.

Representative Academic Papers of Dr. Luo Jiamin

According to available records, Dr. Luo Jiamin actively summarizes scientific research achievements in addition to her clinical work. She has published multiple academic papers as first author, with research focused on lung cancer immunotherapy, interventional therapy for liver cancer and comprehensive oncology treatment. Her papers have appeared in Chinese core journals including Chinese Journal of Hepatology and Chongqing Medicine.

1. Luo Jiamin, Li Mengxia. Research progress on the application of immunotherapy combined with local therapy in lung cancer with liver metastasis. Chongqing Medicine, 2023, 52(15): 2362-2367.

Dr. Luo Jiamin was the first author. Published in Chongqing Medicine, a Chinese Science and Technology Core Journal, this paper systematically reviewed the clinical application progress of immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors combined with local therapies such as radiotherapy, interventional therapy and ablation therapy in patients with lung cancer and liver metastasis. The article noted that although immunotherapy has improved the prognosis of patients with advanced lung cancer, patients with liver metastasis derive limited benefit. The synergistic strategy of immunotherapy combined with local therapy is expected to provide better treatment options for patients with this poor prognosis, offering a theoretical reference for the comprehensive treatment of lung cancer with liver metastasis.

2. Luo Jiamin, Luo Xiaoping, et al. Imaging manifestations and transcatheter arterial chemoembolization treatment of primary liver cancer patients with blood supply from the right renal capsular artery. Chinese Journal of Hepatology, 2015, 23(7).

Dr. Luo Jiamin was the first author. Published in Chinese Journal of Hepatology, a core journal supervised by the China Association for Science and Technology and sponsored by the Chinese Medical Association, this study retrospectively analyzed the clinical and imaging data of 23 patients with hepatocellular carcinoma supplied by the right renal capsular artery, and evaluated the efficacy, technical success rate and safety of TACE via the right renal capsular artery. The results showed that the technical success rate of TACE via RRCA was 100%, with an objective response rate of 56.5%, and cumulative survival rates at 6 months and 1 year of 82.6% and 52.2%, respectively. This indicated that superselective TACE for liver cancer supplied by RRCA has a high technical success rate, good safety and clear efficacy, providing important clinical evidence for interventional treatment of liver cancer with special blood supply sources.

3. Luo Jiamin, Luo Xiaoping, Liu Xi, et al. Analysis of factors influencing RIPA involvement in tumor blood supply during initial TACE treatment for primary liver cancer. Journal of Third Military Medical University, 2015, 37(13): 1388-1392.

Dr. Luo Jiamin was the first author. This paper explored the influencing factors and clinical significance of right inferior phrenic artery involvement in tumor blood supply during the first transcatheter arterial chemoembolization (TACE) treatment for patients with primary liver cancer, providing valuable clinical data analysis for comprehensive assessment of tumor-feeding vessels in interventional treatment of liver cancer.

Patient stories
At UNI-ASIA Cancer Hospital, every journey in search of care is marked by courage and hope, and every story bears witness to doctors and patients working together to overcome disease.
More Cases
Patient Lao Chen
Bladder Cancer
China
Patient Lao Chen
A Chinese patient diagnosed with invasive urothelial carcinoma of the bladder experienced repeated postoperative recurrence and multiple metastases. After undergoing several open surgeries and chemotherapy regimens, the patient's condition became physically intolerable. At the end of 2024, the patient was transferred to Chengdu Uni-Asia Hospital, where Professor Liao Zhengyin's team performed CT combined with ultrasound-guided cryoablation of the abdominal wall metastatic lesion. The patient was able to get out of bed and move around the day after the procedure, was discharged smoothly after only five days of hospitalization, and regained a peaceful life.
Ms. Nguyen
Lung Cancer
Vietnam
Ms. Nguyen
A Vietnamese patient, 68 years old, was diagnosed with small-cell neuroendocrine carcinoma of the right lung with metastases in both lungs. She had previously undergone partial resection of the right lung and multiple rounds of chemoradiotherapy. After recurrence and metastasis left her without the option of surgery, she was referred to Chengdu Uni-Asia Hospital by an international referral center. Professor Liao Zhengyin's team performed minimally invasive interventional chemoembolization for her. She was able to get out of bed and move around the day after the procedure; her cough and shortness of breath improved significantly, and she was discharged smoothly a few days later to return home, regaining a normal life.
Catia
Liver Cancer
Philippines
Catia
A 42-year-old Filipino patient was diagnosed with primary liver cancer with intrahepatic metastases and a tumor thrombus in the inferior vena cava (stage IV), and had lost the opportunity for surgical resection. He was referred to Chengdu Uni-Asia Hospital through an international referral center. Professor Luo Xiaoping’s team first performed biliary drainage to relieve jaundice, and after his condition stabilized, carried out hepatic arterial infusion chemotherapy and embolization to control the tumor. After the procedure, his abdominal distension was significantly relieved; he was able to get out of bed the next day and was successfully discharged to return home.
Patient Akun
Liver Cancer
China
Patient Akun
A Chinese patient was diagnosed with liver cancer accompanied by metastasis to the C3 cervical vertebra and a pathological fracture. On admission, he had severe neck pain and markedly limited movement. The Uni-Asia team first performed cervical vertebroplasty to stabilize the vertebra and relieve pain, and on the following day performed transarterial chemoembolization of the hepatic artery to control the intrahepatic tumor. After surgery, his pain was significantly relieved; he was able to get out of his wheelchair and walk, and he was in good spirits at discharge.

Consultation

Consultation Type
Name
Gender
Date of Birth
Nationality
Country of Residence
Phone Number
Email
Your Question
Privacy Policy and Statement

Submitted Successfully

We have received your consultation. Thank you for your trust. A specialist will contact you within 72 hours, so please keep an eye on your phone calls and email.